Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:ANIP NASDAQ:IMCR NASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.64-1.4%$3.83$2.90▼$11.16$321.27M0.182.43 million shs1.76 million shsANIPANI Pharmaceuticals$97.71-1.0%$79.52$52.50▼$99.50$2.12B0.63423,880 shs210,857 shsIMCRImmunocore$35.24-3.6%$33.99$23.15▼$39.33$1.78B0.77272,490 shs184,758 shsVERAVera Therapeutics$23.77-3.1%$22.28$18.53▼$51.61$1.52B1.171.84 million shs1.08 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%-3.70%+0.28%-47.02%-53.81%ANIPANI Pharmaceuticals0.00%+2.48%+11.71%+51.98%+67.00%IMCRImmunocore0.00%-5.27%+7.18%+7.08%+5.04%VERAVera Therapeutics0.00%-1.74%+10.35%+8.79%-36.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.64-1.4%$3.83$2.90▼$11.16$321.27M0.182.43 million shs1.76 million shsANIPANI Pharmaceuticals$97.71-1.0%$79.52$52.50▼$99.50$2.12B0.63423,880 shs210,857 shsIMCRImmunocore$35.24-3.6%$33.99$23.15▼$39.33$1.78B0.77272,490 shs184,758 shsVERAVera Therapeutics$23.77-3.1%$22.28$18.53▼$51.61$1.52B1.171.84 million shs1.08 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%-3.70%+0.28%-47.02%-53.81%ANIPANI Pharmaceuticals0.00%+2.48%+11.71%+51.98%+67.00%IMCRImmunocore0.00%-5.27%+7.18%+7.08%+5.04%VERAVera Therapeutics0.00%-1.74%+10.35%+8.79%-36.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.57Moderate Buy$17.40378.02% UpsideANIPANI Pharmaceuticals 3.10Buy$88.25-9.68% DownsideIMCRImmunocore 2.45Hold$56.8961.43% UpsideVERAVera Therapeutics 2.90Moderate Buy$63.00165.04% UpsideCurrent Analyst Ratings BreakdownLatest ALT, VERA, IMCR, and ANIP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$86.00 ➝ $114.009/4/2025IMCRImmunocoreZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/25/2025IMCRImmunocoreJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.008/21/2025ANIPANI PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/13/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/13/2025ALTAltimmuneUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $24.008/13/2025ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $18.008/11/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$65.00 ➝ $77.008/8/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$84.00 ➝ $93.008/8/2025ANIPANI PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$94.008/7/2025VERAVera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$56.00 ➝ $53.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K16,063.32N/AN/A$1.74 per share2.09ANIPANI Pharmaceuticals$747.40M2.84$7.60 per share12.86$19.11 per share5.11IMCRImmunocore$310.20M5.72N/AN/A$7.20 per share4.89VERAVera TherapeuticsN/AN/AN/AN/A$9.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)ANIPANI Pharmaceuticals-$18.52M-$0.77N/A23.21N/A-1.37%25.03%8.00%11/14/2025 (Estimated)IMCRImmunocore-$51.09M-$0.40N/AN/AN/A-5.70%-5.40%-1.93%11/5/2025 (Estimated)VERAVera Therapeutics-$152.15M-$3.58N/AN/AN/AN/A-46.70%-39.46%11/6/2025 (Estimated)Latest ALT, VERA, IMCR, and ANIP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ALTAltimmune-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million8/8/2025Q2 2025ANIPANI Pharmaceuticals$1.42$1.80+$0.38$0.36$187.18 million$211.37 million8/7/2025Q2 2025IMCRImmunocore-$0.21-$0.20+$0.01-$0.20$122.96 million$130.65 million8/5/2025Q2 2025VERAVera Therapeutics-$0.82-$1.20-$0.38-$1.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.0920.4420.44ANIPANI Pharmaceuticals1.392.541.96IMCRImmunocore1.015.895.86VERAVera Therapeutics0.1617.0317.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%ANIPANI Pharmaceuticals76.05%IMCRImmunocore84.50%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.40%ANIPANI Pharmaceuticals11.10%IMCRImmunocore10.40%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5088.26 million84.37 millionOptionableANIPANI Pharmaceuticals60021.70 million18.94 millionOptionableIMCRImmunocore32050.39 million45.15 millionOptionableVERAVera Therapeutics4063.82 million53.42 millionOptionableALT, VERA, IMCR, and ANIP HeadlinesRecent News About These CompaniesDynamic Technology Lab Private Ltd Makes New $326,000 Investment in Vera Therapeutics, Inc. $VERA5 hours ago | marketbeat.comSiren L.L.C. Has $17.95 Million Stake in Vera Therapeutics, Inc. $VERASeptember 13 at 3:12 AM | marketbeat.comWoodline Partners LP Has $24.04 Million Stock Holdings in Vera Therapeutics, Inc. $VERASeptember 12 at 6:41 AM | marketbeat.comVera Therapeutics (VERA) Stock Surges 27% Over Last MonthSeptember 10, 2025 | finance.yahoo.comSamlyn Capital LLC Sells 683,797 Shares of Vera Therapeutics, Inc. $VERASeptember 8, 2025 | marketbeat.comParkman Healthcare Partners LLC Acquires New Stake in Vera Therapeutics, Inc. $VERASeptember 8, 2025 | marketbeat.comCinctive Capital Management LP Cuts Stock Holdings in Vera Therapeutics, Inc. $VERASeptember 8, 2025 | marketbeat.comVera Therapeutics, Inc. $VERA Stock Position Lifted by Trexquant Investment LPSeptember 8, 2025 | marketbeat.comNorthern Trust Corp Sells 36,748 Shares of Vera Therapeutics, Inc. $VERASeptember 8, 2025 | marketbeat.comVera Therapeutics, Inc. $VERA Shares Bought by EFG Asset Management North America Corp.September 6, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives $63.00 Consensus Price Target from BrokeragesSeptember 6, 2025 | americanbankingnews.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comVera Therapeutics, Inc. (VERA) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeptember 5, 2025 | seekingalpha.comFirst Light Asset Management LLC Sells 85,367 Shares of Vera Therapeutics, Inc. $VERASeptember 4, 2025 | marketbeat.comVestal Point Capital LP Increases Stake in Vera Therapeutics, Inc. $VERASeptember 4, 2025 | marketbeat.comMPM Bioimpact LLC Grows Position in Vera Therapeutics, Inc. $VERASeptember 4, 2025 | marketbeat.comMagnetar Financial LLC Takes Position in Vera Therapeutics, Inc. $VERASeptember 4, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 4, 2025 | marketbeat.comArmistice Capital LLC Grows Holdings in Vera Therapeutics, Inc. $VERASeptember 2, 2025 | marketbeat.comJump Financial LLC Invests $906,000 in Vera Therapeutics, Inc. $VERASeptember 2, 2025 | marketbeat.comTri Locum Partners LP Invests $3.61 Million in Vera Therapeutics, Inc. $VERAAugust 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Medtronic: The Opportunity Gets Healthier for Income InvestorsBy Thomas Hughes | August 19, 2025Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksBy Thomas Hughes | August 19, 2025BJ’s Wholesale Club Pulls Back to Trend: It’s Time for an EntryBy Thomas Hughes | August 25, 2025ALT, VERA, IMCR, and ANIP Company DescriptionsAltimmune NASDAQ:ALT$3.64 -0.05 (-1.36%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.65 +0.01 (+0.27%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.ANI Pharmaceuticals NASDAQ:ANIP$97.71 -1.02 (-1.03%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$97.76 +0.05 (+0.05%) As of 09/12/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Immunocore NASDAQ:IMCR$35.24 -1.33 (-3.64%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$36.66 +1.42 (+4.03%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Vera Therapeutics NASDAQ:VERA$23.77 -0.76 (-3.10%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$23.54 -0.23 (-0.97%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
